Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine A Janeway

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
International Journal of Radiation Oncology, Biology, Physics|October 27, 2022
Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology GroupSafia K Ahmed, Brent G Witten, William S Harmsen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 2, 2017
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology GroupSafia K Ahmed, R Lor Randall, Steven G DuBois, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2022
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology GroupPooja Hingorani, Mark Krailo, Allen Buxton, et al.
Genome Medicine|January 24, 2013
MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32Andrew D Kelly, Benjamin Haibe-Kains, Katherine A Janeway, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcomaSarah Tannenbaum-Dvir, Julia L Glade Bender, Alanna J Church, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST ClinicChristopher B Weldon, Arin L Madenci, Sosipatros A Boikos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2022
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcomaAxel Budde, Katja Baust, Leonie Weinhold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2020
Genomic and Immunologic Characterization of INI1-Deficient Pediatric CancersSuzanne J Forrest, Alyaa Al-Ibraheemi, Duong Doan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II StudyMargaret von Mehren, Suzanne George, Michael C Heinrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology GroupKatherine A Janeway, Alexander J Chou, Allen Buxton, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
International Journal of Radiation Oncology, Biology, Physics|October 27, 2022
Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology GroupSafia K Ahmed, Brent G Witten, William S Harmsen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 2, 2017
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology GroupSafia K Ahmed, R Lor Randall, Steven G DuBois, et al.
European Journal of Cancer (Oxford, England : 1990)|July 9, 2022
Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology GroupPooja Hingorani, Mark Krailo, Allen Buxton, et al.
Genome Medicine|January 24, 2013
MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32Andrew D Kelly, Benjamin Haibe-Kains, Katherine A Janeway, et al.
Cold Spring Harbor Molecular Case Studies|May 6, 2016
Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcomaSarah Tannenbaum-Dvir, Julia L Glade Bender, Alanna J Church, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST ClinicChristopher B Weldon, Arin L Madenci, Sosipatros A Boikos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2022
Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcomaAxel Budde, Katja Baust, Leonie Weinhold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2020
Genomic and Immunologic Characterization of INI1-Deficient Pediatric CancersSuzanne J Forrest, Alyaa Al-Ibraheemi, Duong Doan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II StudyMargaret von Mehren, Suzanne George, Michael C Heinrich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2025
A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology GroupKatherine A Janeway, Alexander J Chou, Allen Buxton, et al.
Pageof 15